NuvoAir Aos, a sensor created by NuvoAir to detect how persons with COPD (chronic obstructive pulmonary disease) or asthma utilize inhalers, is now accessible in Europe, according to the firm.
In Europe, the sensor is classified as a Class I medical device, which means it is non-invasive and presents a low danger to users. Following approval by the US FDA (Food and Drug Administration), NuvoAir Aos is slated to launch in the United States next year.
The NuvoAir Aos sensor intends to solve these concerns by delivering more information about how inhalers are utilized to patients and professionals. The sensor works with both quick-acting relieving inhalers and long-term maintenance or preventer inhalers and may be fitted to pressurized metered-dose inhalers.The sensor in maintenance inhalers can assist monitor if a drug is being taken correctly to enhance efficacy. The sensor can measure variations in the use of quick-acting relief inhalers over time. Increased usage of a relief inhaler indicates that a person is having greater symptoms and may need to change their medication.